Lilly launches Mounjaro KwikPen in India, matches vial pricing for diabetes and obesity

Mounjaro

Eli Lilly on Wednesday has launched its once-weekly injectable Mounjaro KwikPen (tirzepatide) across India, offering a more convenient delivery format for adults with type 2 diabetes and obesity. The prefilled pen, approved by the Central Drugs Standard Control Organisation (CDSCO), is available in six dose strengths ranging from 2.5 mg to 15 mg.

Each KwikPen contains four doses, designed for single-patient use, and is priced between Rs 14,000 and Rs 27,500 per month depending on strength. The launch aligns with Lilly’s strategy to personalise treatment and improve adherence through simplified administration.

“This innovation supports healthcare professionals in delivering more personalized and effective treatment plans,” said Winselow Tucker, President and GM of Lilly India.

The KwikPen pricing mirrors that of the previously available single-use vials. However the higher doses (7.5 mg to 15 mg) are exclusive to the KwikPen format, priced at Rs 22,000 to Rs 27,500 per month.

The KwikPen offers added convenience and dosing precision, potentially improving patient compliance. Both formats require refrigeration and are available only via prescription.

Mounjaro is seeing strong market traction in India, with monthly sales value jumped from Rs 3 crore in March 2025 to Rs 47 crore in July 2025 — a 15x increase in just five months. Units sold surged from 12,000 in March to 157,000 in July, indicating rapid patient adoption.

Novo Nordisk, which sells rival weight loss drug Wegovy (semaglutide), has already launched it in pre-filled pen formulation.